ISRCTN72153214已完成不适用
A Multinational Double-Blind, Randomised Phase IIb Cooperative Group Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Chemotherapy and/or Endocrine Therapy in Patients with Locally Recurrent or Metastatic Breast Cancer
Fondazione Michelangelo (Italy)0 个研究点目标入组 220 人开始时间: 2010年4月6日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •1. Female patients with histologically or cytologically confirmed adenocarcinoma of the breast.
- •2. Measurable or evaluable locally recurrent or metastatic disease. (Locally recurrent disease must not be amenable to resection with curative intent.) All scans used to document measurable or evaluable disease must be done within 4 weeks prior to randomisation.
- •3. Age greater than or equal to 18 years . Women who are ER+ or PgR+ and candidates for endocrine therapy, must be post-menopausal as defined below:
- •3.1. Bilateral oophorectomy; or
- •3.2. No menses for at least 12 months in patients with an intact uterus, not on gonadatropin suppressing agents; or
- •3.3. Follicle-stimulating hormone (FSH) in postmenopausal range in patients <60 years without prior hysterectomy; or
- •3.4. Pre-menopausal women undergoing pharmacological ovarian ablation.
- •4. Any adjuvant or neoadjuvant taxane therapy must have been completed at least 12 months prior to randomisation should the patient be candidate to start present study treatment with chemotherapy.
- •5. Patients must have discontinued other adjuvant chemotherapy at least 3 weeks prior to randomisation.
- •6. Adjuvant aromatase inhibitors must have been completed at least 3 months prior to randomisation.
- •7. Adjuvant tamoxifen must have been completed at least 4 weeks prior to randomisation
- •8. Prior radiation therapy is allowed but must be completed at least 3 weeks prior to randomisation, with all acute toxicities recovered to baseline status. Previously radiated area(s) must not be the only site of disease and must not correspond to more than 25% of the bone marrow producing areas for patients who are candidate for chemotherapy.
- •9. ECOG Performance Status of 0 or 1
- •10. Adequate bone marrow, liver, and renal function as assessed by the following:
- •10.1. Haemoglobin equal or greater than 9.0 g/dl
- •10.2. Absolute neutrophil count (ANC) equal or greater than 1,500 x 10^9/L
- •10.3. Platelet count equal or greater than 100,000 x 10^9/L
- •10.4. Total bilirubin lesser than or equal to 1.5 times the upper limit of normal (ULN)
- •10.5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) lesser than or equal to 2.5 x ULN (lesser than or equal to 5 x ULN for patients with liver involvement)
- •10.6. International Normalised Ratio for Prothrombin Time (PT-INR) lesser than or equal to 1.5 and activated prothrombin time (aPTT) within normal limits.
- •10.7. Patients receiving anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate. For patients on warfarin, the INR should be measured prior to initiation of sorafenib/placebo and monitored at least weekly, or as defined by the local standard of care, until INR is stable.
- •10.8. Creatinine lesser than or equal to 1.5 times the upper limit of normal.
- •11. Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to randomisation, and patients must agree to use adequate contraception (barrier method of birth control) prior to randomisation, for the duration of study participation, and for 28 days after the last dose of study treatment.
- •12. Patients must be willing and able to sign a written informed consent. A signed informed consent must be appropriately obtained prior to any study specific procedures.
- •13. Patients must be able to swallow, retain, and absorb whole oral tablets.
排除标准
- •1. Patients with breast cancer over-expressing human epidermal growth factor receptor 2 (HER2) [gene amplification by fluorescence in situ hybridisation (FISH) or 3+ over-expression by immunohistochemistry (IHC)]. Patients with unknown HER-2 status are not eligible.
- •2. Patients with active brain metastases. Patients with neurological symptoms must undergo a contrast CT scan or MRI of the brain to exclude active brain metastasis. Patients with treated brain metastases are eligible provided they have no evidence of disease and are off definitive therapy (including steroids) at least 3 months prior to randomisation.
- •3. Prior chemotherapy or endocrine therapy for locally recurrent or metastatic breast cancer.
- •4. Patients with unknown hormone receptor status.
- •5. Patients who are ER+ or PgR+ and are pre-menopausal and unwilling to undergo pharmacological ovarian ablation
- •6. Women who are pregnant or breast-feeding.
- •7. Major surgery, open biopsy, or significant traumatic injury within 4 weeks of randomisation.
- •8. Evidence or history of bleeding diathesis or coagulopathy.
- •9. Serious, non-healing wound, ulcer, or bone fracture.
- •10. Substance abuse or medical, psychological, or social condition that may interfere with the patient?s participation in the study or evaluation of the study results.
- •11. Pre-existing peripheral neuropathy equal to or greater than grade 2.
- •12. Use of cytochrome P450 enzyme-inducing anti-epileptic drugs (such as phenytoin, carbamazepine, or phenobarbital) is not allowed.
- •13. Cardiac disease:
- •13.1. Congestive heart failure >class II New York Heart Association (NYHA) or
- •13.2. Unstable angina (anginal symptoms at rest), or new-onset angina (begun within the last 3 months), or myocardial infarction within the 6 months prior to randomisation, or
- •13.3. Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.
- •14. Uncontrolled hypertension (systolic blood pressure greater than 150 mm Hg or diastolic pressure greater than 90 mm Hg) despite optimal medical management.
- •15. Thrombolic, embolic, venous, or arterial events, such as a cerebrovascular accident including transient ischemic attacks within the past 6 months.
- •16. Pulmonary haemorrhage/bleeding event greater than National Cancer Institute (NCI-CTCAE) Grade 2 within 4 weeks of first dose of study drug.
- •17. Any other haemorrhage/bleeding event greater than NCI-CTCAE Grade 3 within 4 weeks of randomisation.
- •18. Active clinically serious infection greater than NCI-CTCAE Grade 2.
- •19. Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C.
- •20. Previous or concurrent cancer that is distinct in primary site or histology from breast cancer EXCEPT cervical cancer in-situ, treated basal cell carcinoma, superficial bladder tumours [Ta and Tis], or any cancer curatively treated >5 years prior to randomisation.
- •21. Known or suspected allergy to sorafenib, letrozole or hypersensitivity to docetaxel or drugs using the vehicles polysorbate 80 or ethanol.
- •22. Prior or concurrent use of St. John?s Wort or rifampin (rifampicin) within 1 week of randomisation.
- •23. Prior or concurrent treatment with any agent that targets vascular endothelial growth factor (VEGF) or VEGF receptors (VEGFR) (licensed or investigational).
- •24. Use of an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding randomisation.
研究者
相似试验
进行中（未招募）
不适用
A Multinational Double-Blind, Randomized Phase IIb Cooperative Group Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Chemotherapy and/or Endocrine Therapy in Patients with Locally Recurrent or Metastatic Breast Cancer - NDPatients with Locally Recurrent or Metastatic Breast CancerMedDRA version: 9.1Level: LLTClassification code 10055113Term: Breast cancer metastaticEUCTR2007-001416-23-ITFONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E CURA DEI TUMORI220
进行中（未招募）
不适用
A Multinational Double-Blind, Randomized Phase IIb Cooperative Group Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Chemotherapy and/or Endocrine Therapy in Patients with Locally Recurrent or Metastatic Breast CancerEUCTR2007-001416-23-DEFONDAZIONE MICHELANGELO220
进行中（未招募）
1 期
A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancerocally Advanced or Metastatic Breast CancerMedDRA version: 9.1Level: LLTClassification code 10055113Term: Breast cancer metastaticEUCTR2007-000290-32-FRSOLTI229
进行中（未招募）
不适用
A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast CancerEstudio fase 2b, multinacional, doble ciego y aleatorizado para evaluar la eficacia y seguridad de sorafenib frente a placebo administrados junto con capecitabina en pacientes con cáncer de mama localmente avanzado o metastásicoocally Advanced or Metastatic Breast CancerCáncer de Mama Localmente Avanzado o MetastásicoMedDRA version: 9.1Level: LLTClassification code 10055113Term: Breast cancer metastaticEUCTR2007-000290-32-ESSOLTI220
进行中（未招募）
1 期
Study to investigate the use of benralizumab in chronic spontaneous urticariaEUCTR2020-000169-17-DEAstraZeneca AB160